依美昔單抗 (INN :ecromeximab;開發代號:KW2871 )是一種嵌合單株抗體 ,正在開發用於治療惡性黑色素瘤 。[ 1] [ 2] 該藥物被用來針對轉移性黑色素瘤 進行I期臨床試驗,[ 3] 並在隨後與高劑量的干擾素α2b 聯合進行了II期臨床試驗。[ 4] [ 5]
該藥物由協和發酵工業株式會社開發。截至2015年12月,開發已停止。[ 6]
參考資料
^ Statement On A Nonproprietary Name Adopted By The USAN Council - Ecromeximab (頁面存檔備份 ,存於互聯網檔案館 ), American Medical Association .
^ Clinical trial number NCT00679289 for "Phase II Study of KW2871 Combined With High Dose Interferon-alpha2b in Patients With Metastatic Cutaneous Melanoma" at ClinicalTrials.gov
^ Forero, Andres; Shah, Jatin; Carlisle, Ronda; Triozzi, Pierre L.; LoBuglio, Albert F.; Wang, Wen-Quan; Fujimori, Matt; Conry, Robert M. A phase I study of an anti-GD3 monoclonal antibody, KW-2871, in patients with metastatic melanoma . Cancer Biotherapy & Radiopharmaceuticals. 2006-12, 21 (6) [2024-03-06 ] . ISSN 1084-9785 . PMID 17257071 . doi:10.1089/cbr.2006.21.561 . (原始內容存檔 於2024-06-04).
^ Phase II Study of KW2871 Combined With High Dose Interferon-α2b in Patients With Metastatic Melanoma - Full Text View - ClinicalTrials.gov . clinicaltrials.gov. [2024-03-06 ] . (原始內容存檔 於2021-04-10) (英語) .
^ Tarhini, Ahmad A.; Moschos, Stergios J.; Lin, Yan; Lin, Hui-Min; Sander, Cindy; Yin, Yan; Venhaus, Ralph; Gajewski, Thomas F.; Kirkwood, John M. Safety and efficacy of the antiganglioside GD3 antibody ecromeximab (KW2871) combined with high-dose interferon-α2b in patients with metastatic melanoma . Melanoma Research. 2017-08, 27 (4) [2024-03-06 ] . ISSN 1473-5636 . PMID 28489678 . doi:10.1097/CMR.0000000000000353 . (原始內容存檔 於2024-06-03).
^ Adis insight: Ecromeximab . [2024-03-06 ] . (原始內容存檔 於2017-01-03).